REVELATION BIOSCIENCES, INC.

REVELATION BIOSCIENCES, INC.

Revelation Biosciences was incorporated in Delaware in 2020 and headquartered in San Diego, California. The company went public via a direct listing in January 2022, trading on Nasdaq under the ticker REVB. CEO James Rolke assumed the role in January 2024, succeeding the founding management team. The firm operates a hybrid model: it commercializes a topical antiseptic product while maintaining a legacy immunotherapy pipeline inherited from its predecessor entity. Revenue currently derives from REVSA-25, an over-the-counter povidone-iodine nasal swab launched under the commercial brand 'GermBlast Protect,' marketed for infection prevention. The biotech side of the business licenses and develops repurposed immunomodulators, with disclosed programs evaluating phosphorylated hexaacyl disaccharide (PHAD) in chronic kidney disease and acute kidney injury models. The firm has not publicly named co-development partners, co-investors, or large-scale institutional backers beyond its status as a Nasdaq-listed entity. Geographically, operations center on the US, with clinical and commercial activities run domestically. As a micro-cap public company with no disclosed institutional pharma partnerships, Revelation employs a lean outsourced development model to minimize cash burn. The company reported cash and equivalents of approximately $5.2 million as of its most recent SEC filing. An April 2025 1-for-12 reverse stock split allowed the firm to maintain Nasdaq listing compliance. Proceeds from periodic at-the-market equity offerings fund operations, with no venture-capital or single-family backing disclosed. Adjacent vehicles or philanthropic structures have not been identified. The firm's structural differentiator is its operational identity as a publicly traded asset manager within a biotech wrapper — revenue comes from an antiseptic swab, not a blockbuster drug, while the treasury is run with the liquidity-minded posture of a small registered fund. This dual track creates a capital structure where commercial hygiene-product sales and ATM equity issuances jointly sustain the clinical pipeline, rather than relying on milestone payments or large pharmaceutical alliances.